Airbus SE is falling behind on deliveries of the A321XLR, a longer-range version of its most popular jet, with Indian customer IndiGo unlikely to receive the full batch of nine units this year, according to people familiar with the matter. InterGlobe Aviation Ltd. , the operator of Asia’s largest low-cost carrier, was supposed to receive the XLRs by year’s end , but the time frame on some units ha...
Airbus SE is falling behind on deliveries of the A321XLR, a longer-range version of its most popular jet, with Indian customer IndiGo unlikely to receive the full batch of nine units this year, according to people familiar with the matter. InterGlobe Aviation Ltd. , the operator of Asia’s largest low-cost carrier, was supposed to receive the XLRs by year’s end , but the time frame on some units has been pushed back by several months, said the people, asking not to be identified because the information isn’t public. IndiGo has received two XLR jets so far, and they’re being used on routes to Athens and Istanbul. The airline was told the Middle East war is disrupting the planemaker’s supply chain, the people said. IndiGo is now negotiating with the France-based manufacturer for favorable delivery slots, the people said. An Airbus spokesperson said the company doesn’t comment on delivery schedules agreed upon with customers. IndiGo declined to comment. The XLR, which stands for “extra long range,” is meant to open long-haul routes for budget airlines that fly single-aisle aircraft rather than the more complex widebody models. IndiGo placed an order for 40 of the new aircraft. The XLR delays would represent another hurdle for IndiGo’s ambitious international expansion , which is under pressure from soaring jet-fuel costs and airspace restrictions. The carrier reported an unexpected loss in the first quarter and said this week it was suspending flights to Hong Kong and Shanghai until at least October. Airbus began delivering the XLR to customers last year. The plane combines the economics of a narrowbody aircraft with the range of a longer-range model such as the bigger A330. At the same time, flying long routes with an single-aisle airframe comes with operational complexities, making the aircraft more of a niche choice than the popular A321.
The decision to extend Clarke’s contract before his side have proved they can finally progress to the knockouts could be a needless risk The summit of Scottish football provides a wonderful environment for those who value long-term career stops. Neil Doncaster, chief executive of the Scottish Professional Football League, arrived at the then Scottish Premier League in 2009. Ian Maxwell, bizarrely ...
The decision to extend Clarke’s contract before his side have proved they can finally progress to the knockouts could be a needless risk The summit of Scottish football provides a wonderful environment for those who value long-term career stops. Neil Doncaster, chief executive of the Scottish Professional Football League, arrived at the then Scottish Premier League in 2009. Ian Maxwell, bizarrely headhunted from relegation-bound Partick Thistle, has been the Scottish Football Association’s chief executive since 2018. Scot Gemmill’s tenure as the nation’s under-21 manager has lasted a decade despite underwhelming results. Glass half full or half empty; either this is a domain that delivers admirable continuity or one in which no one makes sufficient progress to appeal to those in bigger ponds. Continue reading...
The Roundhill Memory ETF (CBOE:DRAM) is the first U.S.-listed pure-play memory-chip ETF, and it landed in the middle of one of the most violent upcycles the industry has ever seen. DRAM launched on April 2, 2026 with a 0.65% expense ratio, just as Micron Technology (NASDAQ:MU) was approaching a trillion-dollar market cap. Micron is up ... Memory Chip Prices Will Make or Break DRAM ETF Before Year-...
The Roundhill Memory ETF (CBOE:DRAM) is the first U.S.-listed pure-play memory-chip ETF, and it landed in the middle of one of the most violent upcycles the industry has ever seen. DRAM launched on April 2, 2026 with a 0.65% expense ratio, just as Micron Technology (NASDAQ:MU) was approaching a trillion-dollar market cap. Micron is up ... Memory Chip Prices Will Make or Break DRAM ETF Before Year-End 2026
For retirement-focused investors weighing the two dominant independent power producers cashing in on the AI data center buildout, the question is direct: Vistra (NYSE:VST) or Constellation Energy (NASDAQ:CEG) — which one belongs in the portfolio right now? Both have ridden the same nuclear-and-gas thesis. Both have signed long-term hyperscaler contracts. But the answer for someone whose ... Vistra...
For retirement-focused investors weighing the two dominant independent power producers cashing in on the AI data center buildout, the question is direct: Vistra (NYSE:VST) or Constellation Energy (NASDAQ:CEG) — which one belongs in the portfolio right now? Both have ridden the same nuclear-and-gas thesis. Both have signed long-term hyperscaler contracts. But the answer for someone whose ... Vistra vs. Constellation: Which AI Power Stock Is the Better Buy Right Now?
Welcome to the Business of Food newsletter, covering how the world feeds itself in a changing economy and climate. This week, Joe Lovinger reports from Texas on preparations for the screwworm. Any tips or feedback? Email Agnieszka de Sousa . And to receive this newsletter, please sign up here . Flesh Eater It was only a matter of time. After creeping up on the US for years, the deadly, flesh-eatin...
Welcome to the Business of Food newsletter, covering how the world feeds itself in a changing economy and climate. This week, Joe Lovinger reports from Texas on preparations for the screwworm. Any tips or feedback? Email Agnieszka de Sousa . And to receive this newsletter, please sign up here . Flesh Eater It was only a matter of time. After creeping up on the US for years, the deadly, flesh-eating parasite has made it to Texas, threatening to infiltrate cattle herds and inflate the cost of your steak. A case of the New World screwworm was confirmed on Wednesday, marking the first detection in the US in almost a decade. Like a screw twisting into wood, the larvae of this fly burrow into the living tissue of cows, causing severe damage and even death. (For more gruesome details, read this Explainer ). Its potentially destructive impact is equally menacing. The American herd is already the smallest in 75 years and Donald Trump’s administration is battling record-high beef prices . The screwworm case could prompt import bans on US beef, leading to losses for meatpackers. The screwworm adds to a long list of diseases that have ravaged livestock globally in recent years in a threat to food supplies . There’s African swine fever , bird flu , lumpy skin disease, foot-and-mouth disease and bluetongue — just to name a few. Cases are becoming more frequent and harder to contain because of growing trade and movement of people and animals, while climate change helps pathogens thrive . The good news is that surveillance and detection are better than before. Ranchers in Texas are now gearing up to take on a threat they’d been warned about. Donnell Brown, a fifth-generation Texan cattle rancher, has stocked up on aerosol spray to treat infestations and if the pest reaches his town of Throckmorton, he’s got a deworming medicine for his calves. Brown expected screwworm to arrive in the state eventually, but still felt surprised when the news came this week. “It’s kind of like when y...
In this article EWT GEM EWY EEM Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:59 02:59 Where to find innovation in the ETF industry; Anthropic confidentially files for IPO ETF Edge The next massive gains in artificial intelligence may come from thousands of miles away. Tim Urbanowicz, chief investment strategist at Innovator from Goldman Sachs Asset Management, is urging invest...
In this article EWT GEM EWY EEM Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 2:59 02:59 Where to find innovation in the ETF industry; Anthropic confidentially files for IPO ETF Edge The next massive gains in artificial intelligence may come from thousands of miles away. Tim Urbanowicz, chief investment strategist at Innovator from Goldman Sachs Asset Management, is urging investors to look beyond their backyards to the emerging markets. "[It's] where a lot of the big money can be made on the AI trade," he told CNBC's " ETF Edge " this week – calling it "the next big wave." Urbanowicz is particularly bullish on Taiwan and South Korea when it comes to the AI build-out. He notes they are a big part of the broad iShares MSCI Emerging Markets ETF , which is up 26% as of Thursday's close. "These are major players in the AI trade and the AI space where valuations really haven't gone up as much as they have in the U.S." he said. "There's still a lot of runway in our view to provide outsized gains with this AI trade." The iShares MSCI Taiwan ETF is up almost 67% so far this year while the iShares MSCI South Korea ETF market has risen 109%, as of Thursday's U.S. close. Both Taiwan- and South Korea-focused ETFs hold several AI memory-related chip names. In a special note to CNBC, Urbanowicz highlighted the actively managed Goldman Sachs ActiveBeta Emerging Markets Equity ETF as a way for investors to gain exposure to potential AI-driven gains in emerging markets. Stock Chart Icon Stock chart icon Getting exposure to AI abroad Yet, Urbanowicz isn't abandoning the domestic trade when it comes to AI. "We think the U.S. is still positioned for success," he said. Disclaimer Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Shares in multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) soared by 31.6% in May, according to data from S&P Global Market Intelligence . The move came as investors bought the stock on optimism that management's presentation at the annual American Society of Clinical Oncology meeting at the end of the month would strengthen the case for the Galleri test's approval by the Food...
Shares in multi-cancer early detection (MCED) test company Grail (NASDAQ: GRAL) soared by 31.6% in May, according to data from S&P Global Market Intelligence . The move came as investors bought the stock on optimism that management's presentation at the annual American Society of Clinical Oncology meeting at the end of the month would strengthen the case for the Galleri test's approval by the Food and Drug Administration (FDA) and, ultimately, for medical insurance coverage. The presentation gained increased importance following the failure of its 50-cancer MCED Galleri test to meet a primary endpoint in a landmark 3-year trial conducted by England's National Health Service (NHS). The trial aimed to demonstrate a statistically significant reduction in the detection of Stage III and Stage IV (combined) cancers by detecting cancers at earlier stages in a test group compared to a control group. Unfortunately, the trial failed to meet this endpoint, causing the slump you can see in the price chart below in February. As often with clinical trials, it's not quite cut and dried, and in February's press release, management noted a few key points: Continue reading
(Bloomberg) -- If SpaceX’s IPO goes off as planned, it’ll be a pivotal moment for many of the company’s thousands of employees, who’ll finally be able to sell shares into the public market.Most Read from BloombergSpaceX, Other Mega IPOs Denied Fast Index Entry by S&PSaylor’s Bitcoin Machine Is Misfiring on Every Cylinder‘Sell Indonesia’ Sweeps Trading Desks as Prabowo Tightens GripGlazer Family Me...
(Bloomberg) -- If SpaceX’s IPO goes off as planned, it’ll be a pivotal moment for many of the company’s thousands of employees, who’ll finally be able to sell shares into the public market.Most Read from BloombergSpaceX, Other Mega IPOs Denied Fast Index Entry by S&PSaylor’s Bitcoin Machine Is Misfiring on Every Cylinder‘Sell Indonesia’ Sweeps Trading Desks as Prabowo Tightens GripGlazer Family Members Study Manchester United Stake SaleBloomberg Retracts Incorrect Story on RBI GoldThat prospect
hapabapa/iStock Editorial via Getty Images Introduction It’s time to talk about the market again. But this won’t be your “average” market article where we talk about sentiment, technicals, and stuff like that. It’s not like I have written much on that in the past, but still. Especially in an age of AI, where you can just let some robot look into a stock for you (I highly advise against that, by th...
hapabapa/iStock Editorial via Getty Images Introduction It’s time to talk about the market again. But this won’t be your “average” market article where we talk about sentiment, technicals, and stuff like that. It’s not like I have written much on that in the past, but still. Especially in an age of AI, where you can just let some robot look into a stock for you (I highly advise against that, by the way!), we need to spend our time wisely, which means unpacking Big Picture developments that can provide us with the opportunity to generate long-term alpha, reposition our portfolios more favorably, and even turn some risks into tailwinds. That’s exactly what this article is about, as we need to discuss a few very important topics, including the market’s top-heavy nature, new economic developments, and what these mean for investors. Oh, right. And I get to brag a bit. But first, let’s dive into the top-heavy nature of the market. The Market is Top-Heavy What else is new? This isn’t a surprising subheader, as I have given a lot of attention to this development for more than a year. I think it’s fair to say that this isn’t a “normal” market by any means. Going into this month, the ten biggest S&P 500 ( SP500 ) stocks accounted for 40% of its weighting. JPMorgan That’s not necessarily a problem, as these are the very stocks that are causing the market to reach new highs. As the equal-weight S&P 500 ( RSP ) versus market-weight S&P 500 ( SPY ) ratio below shows, since 2015, the increasingly top-heavy nature of the market has been a good thing for S&P 500 investors (and anyone who owns Big Tech, of course). TradingView (RSP/SPY Total Return Ratio) And then there’s the valuation. At slightly more than 21x forward earnings (see below), the market is far from cheap, which adds to risks and “bubble talk.” If I wanted to write a bearish article for clicks only, I would probably tell you how dangerous it is that this market is carried by just a few stocks that have created a very u...
zimmytws/iStock via Getty Images On Wednesday, June 10, 2026, the Bureau of Labor Statistics will issue a news release on the Consumer Price Index for May. Together with the non-farm payroll report, the Federal Reserve will decide whether to hold or cut interest rates. At the next FOMC meeting later this month, newly appointed Fed Chair Kevin Warsh will announce that decision. Stock markets are la...
zimmytws/iStock via Getty Images On Wednesday, June 10, 2026, the Bureau of Labor Statistics will issue a news release on the Consumer Price Index for May. Together with the non-farm payroll report, the Federal Reserve will decide whether to hold or cut interest rates. At the next FOMC meeting later this month, newly appointed Fed Chair Kevin Warsh will announce that decision. Stock markets are largely dismissive of expectations of a red-hot inflation report. When I posted a preview last month on WTI crude ( CL1:COM ) prices lifting CPI, rating the S&P 500 ( IVV ) ( VOO ) ( SPY ) worked out. The index gained 2.51% to close near its all-time high. What might the May CPI report reveal? Stock market trading activity will not likely react to the data. The Dow Jones ( DJI ) and Nasdaq ( QQQ ) are enthusiastic about the upcoming SpaceX’s ( SPCX ) initial public offering. That will raise around $75 billion , valuing the firm at around $1.8 trillion. Three Months of Temporary Energy Inflation Since the Iran conflict started in February, the Strait of Hormuz has remained closed. In the last Fed meeting, then Fed Chair Jerome Powell characterized energy inflation along the lines of temporary/transitory. In the first half of May, WTI crude traded in the range of $95 per barrel to over $105. For energy investors, May 14 played out as the peak for oil prices. WTI crude (OilPrice.com) Oil prices fell sharply toward the end of last month to around $88/bbl. Ongoing hopes that the U.S. would agree to a peace framework with Iran suggest that crude prices will continue to trend at $90/bbl or lower. Even if the conflict between Israel and Lebanon persists and the U.S. and Iran exchange attacks, oil prices are losing momentum. In April, the index for energy increased by 3.8%. That accounted for over 40% of the all-items increase. That is down from 10.9% in March. In the last 12 months, the index for energy increased by 17.9%. CPI percent changes (BLS) The table above shows that the inde...
Getty Images Palvella Therapeutics, Inc. ( PVLA ) is a rare-disease dermatology company built around its proprietary QTORIN platform. QTORIN helps reformulate known active molecules for topical treatments of underserved skin and vascular malformation disorders. Their main drug candidate right now is QTORIN rapamycin for microcystic lymphatic malformations (mLM), which has already reported positive...
Getty Images Palvella Therapeutics, Inc. ( PVLA ) is a rare-disease dermatology company built around its proprietary QTORIN platform. QTORIN helps reformulate known active molecules for topical treatments of underserved skin and vascular malformation disorders. Their main drug candidate right now is QTORIN rapamycin for microcystic lymphatic malformations (mLM), which has already reported positive Phase 3 data. PVLA subsequently held a pre-NDA meeting with the FDA, and management believes they may be able to move it forward without an additional efficacy study. That’s why they’ve reaffirmed their 2H2026 NDA timeline. A QTORIN-Led Rare-Disease Story Palvella Therapeutics, Inc. is still a clinical-stage biopharma working on treatments for rare skin diseases and vascular malformations. PVLA was founded back in 2015, and then it went public after merging with Pieris Pharmaceuticals in 2024. They’re currently based in Wayne, Pennsylvania. I believe their main value driver today is easily QTORIN rapamycin for mLM, and it’s also being researched for cutaneous venous malformations (cVM) and angiokeratomas. I also previously covered PVLA in September 2025, and since then, the stock has appreciated by approximately 96.0%. So, I thought it was worthwhile revisiting this name and updating my thesis. Source: Seeking Alpha. As a quick recap, PVLA’s proprietary platform is QTORIN , which is specifically designed for topical applications for rare and chronic diseases. However, what’s interesting about their approach is that it’s potentially safer and more convenient compared to other treatments that often have side effects throughout the rest of the human body. Management believes their main edge is their expertise with formulation and delivery, not just the drug itself. Concretely, QTORIN potentially allows for high drug concentrations, while also providing reasonably good safety and tolerability standards. On top of that, QTORIN can reach specific skin layers where the disease oc...
John Hansard Gallery, Southampton Farewell Sweet Innocence references cinema, football, music and Windrush – it’s about trying to fit in, but always falling short, even as a Turner-nominated artist There’s that old Marxist (Groucho, not Karl) saying about refusing to join any club that would have you as a member. Simeon Barclay takes that idea one step further in his work, because he knows that ev...
John Hansard Gallery, Southampton Farewell Sweet Innocence references cinema, football, music and Windrush – it’s about trying to fit in, but always falling short, even as a Turner-nominated artist There’s that old Marxist (Groucho, not Karl) saying about refusing to join any club that would have you as a member. Simeon Barclay takes that idea one step further in his work, because he knows that even if the club would have him, he’d never be truly accepted anyway. He calls his show in Southampton “a lament of sorts, to access and loss”. It comes just a few weeks after he got nominated for the Turner prize, and it’s a damn fine argument for why he should probably win it. This is an exhibition all about exclusion, about trying to fit in but never quite managing. It’s razor-sharp, funny, pop-cultural, obtuse conceptual art about growing up black in Britain, about trying to make it and knowing you’re bound to fail, because the system is geared towards failure. Continue reading...
Small-cap stocks often provide a growth engine for diversified portfolios, capturing companies before they reach mid-cap status. Both the Vanguard Small-Cap ETF (NYSEMKT:VB) and the iShares Core S&P Small-Cap ETF (NYSEMKT:IJR) are heavyweights in this space, yet they use different indexing strategies to define smallness and select their constituents for long-term exposure. VB offers a lower expens...
Small-cap stocks often provide a growth engine for diversified portfolios, capturing companies before they reach mid-cap status. Both the Vanguard Small-Cap ETF (NYSEMKT:VB) and the iShares Core S&P Small-Cap ETF (NYSEMKT:IJR) are heavyweights in this space, yet they use different indexing strategies to define smallness and select their constituents for long-term exposure. VB offers a lower expense ratio and broader diversification, while IJR provides more concentrated exposure to higher-quality small caps. Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield. VB is the more affordable option with an expense ratio of 0.03%, which is half the cost of IJR. The Vanguard fund also provides a slightly higher trailing-12-month dividend yield of 1.2% compared to 1.16% for its iShares counterpart. Continue reading